Pipeline
jCyte doses first patients in RP allogeneic cell therapy trial
Phase 2b JC02-88 trial to evaluate a single IVT injection of jCell (famzeretcel), an agnostic cell therapy with the potential to restore vision in all RP genetic subtypes.
Products
FDA sends warning letters to three eye drop manufacturers
Agency identifies iVIZIA eye drops, Revitalize Energizing Eye Drops, and FOCUS PI Eye Drops as unapproved new drugs and misbranded products.
Research
How successful are pediatric glaucoma procedures?
Study identifies high failure rate and key factors associated with likelihood of failure.
Research
Prevent Blindness launches diabetes and the eye advisory committee
In partnership with industry professionals, nonprofit seeks to increase awareness and early identification of diabetes-related eye diseases through three key initiatives.
Business
Opthea to lay off 80% of workforce amid executive cuts
Company also announces cuts to Board of Directors as the CEO is among several planned departures beginning in September.
Pipeline
Avista and Forge Biologics partner to advance XLRS gene therapy
Collaboration leverages Forge’s in-house AAV development and manufacturing services for AVST-101, an AAV-based IVT gene therapy.
Research
Researchers identify high-risk patients prone to IOL dislocation
Trauma, high myopia, and glaucoma may place patients at higher risk for intraocular lens dislocation.
Pipeline
FDA green lights Myra Vision's IDE study for glaucoma
IDE approval enables company to initiate the open-label ADAPT study on its proprietary Calibreye TGT Surgical System.
Pipeline
FDA clears Opus Genetics' IND for BEST1 IRD gene therapy
Company plans to initiate phase 1/2 clinical trial on OPGx-BEST1, a potential first-ever treatment for this patient base.
Pipeline
FDA agrees to SPA for Ocular Therapeutix NPDR registrational trial
Agreement includes planned design for study evaluating AXPAXLI (formerly OTX-TIKI), an IVT implant with the potential for long-term durability and fewer injections.
Events
Ophthalmology Tech Forum explores next frontier in retina diagnostics and treatment
Annual industry event covered gene therapy, pipeline treatments, and technology innovations for retinal disease.
Events
Registration opens for Eyes On Retina 2025
The premier virtual event of the year for retina-focused ECPs kicks off in October—with the chance to claim up to 5 hours of CE/CME.
Products
Beyeonics Vision secures US patent for cataract surgical imaging tech
Patent protection extends to the Beyeonics One, a fully digital HD imaging platform enabling 3D visualization of the surgical field.
Pipeline
FDA grants Fast Track designation to AAVantgarde's Stargardt gene therapy
Status benefits clinical study of AAVB-039, an AAV8 intended to address the disease’s root cause by delivering the full-length ABCA4 gene via a single subretinal injection.
Research
Clinical review calls for upper eyelid imaging in meibomian gland evaluations
Study highlights four key areas where upper eyelid assessment can aid in earlier detection of ocular diseases and systemic conditions.
Research
Study: Lumenis' DMSt manages lower lid laxity and blinking quality
Dynamic Muscle Stimulation technology found to benefit management of DED signs and symptoms due to MGD.
Products
Clinicians perform first FDA-approved ENCELTO treatment for MacTel
As the first-ever FDA-approved MacTel therapy, ENCELTO (revakinagene taroretcel-lwey) is a single-dose ocular implant administered via an outpatient vitreoretinal surgery.
Research
TFOS DEWS III report includes use of Lacrifill canalicular gel
Latest installment details two clinical studies validating the use of Nordic Pharma’s FDA-cleared, patented dry eye therapy device.
Research
Cequa's Onset of Action Trial demonstrates rapid ocular surface benefits
Recent data on the FDA-approved, preservative-free eye drop builds on supporting clinical findings—this time for DED patients preparing for refractive-cataract surgery.
Research